Trials / Terminated
TerminatedNCT02644486
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Zhi-Hong Liu, M.D. · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | High dosage Sevelamer Carbonate + Irbesartan | Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d |
| DRUG | Low dosage Sevelamer Carbonate + Irbesartan | Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d |
| DRUG | Irbesartan | Irbesartan 300mg/d |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2015-12-31
- Last updated
- 2018-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02644486. Inclusion in this directory is not an endorsement.